From CNBC: 2024-09-12 11:50:55

Moderna plans to cut $1.1 billion in expenses by 2027 and aims for 10 new product approvals. R&D spending to decrease to $3.6 to $3.8 billion by 2027 with a focus on new research. However, shares dropped over 15% after the announcement. Revenue expected to reach $6 billion by 2028 for break-even.

Positive late-stage trial results announced for Moderna’s RSV vaccine for high-risk adults and a new flu shot for older adults. They have five respiratory shots with positive phase three results. Revenue expected to increase with a compounded annual growth rate of over 25% with new product launches from 2026 to 2028.

Moderna’s RSV vaccine, mRESVIA, met efficacy goals in a study for high-risk adults with no safety concerns. They plan to file for approval for ages 18 to 59 and use a “priority review voucher” for faster FDA review. Company discontinuing RSV vaccine for infants under 2. Stand-alone flu vaccine shows promising results.



Read more at CNBC: $1 billion in cost cuts, 10 product launches planned